NASDAQ:BFRA
Delisted
Biofrontera AG Stock News
$2.67
+0 (+0%)
At Close: Aug 17, 2022
Biofrontera (BFRI) Stock: Why The Price Surged Today
12:15pm, Wednesday, 24'th Nov 2021
The stock price of Biofrontera Inc (NASDAQ: BFRI) increased by over 150% during intraday trading today. This is why it happened.
Global Cancer Photodynamic Therapy Market Synopsis: The credible Cancer Photodynamic Therapy Market report, like other reports, follows certain process flow with several steps. First is product initiation which includes defining project scope, defining timeline and finalizing objectives, and defining timeline. Next
Biofrontera AG announces mediation results
01:45pm, Friday, 19'th Nov 2021 GlobeNewswire Inc.
Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (ISIN: DE0006046113) has been in mediation proceedings with Mr. Wilhelm K. T. Zour
Biofrontera AG announces mediation results
01:45pm, Friday, 19'th Nov 2021 Intrado Digital Media
Leverkusen, Germany, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (ISIN: DE0006046113) has been in mediation proceedings with Mr. Wilhelm K. T. Zours and Deutsche Balaton AG for a year in order to find a solution for the settlement of legal disputes and other differences (see ad hoc announcement of September 11, 2020). Mr. Zours is an indirect major shareholder of Biofrontera AG, holding the shares in Biofrontera AG through various companies (hereinafter "Deutsche Balaton Group"). Another major shareholder is Maruho Deutschland GmbH, a subsidiary of Maruho Co. Ltd, Japan. At the upcoming Annual General Meeting of Biofrontera AG on December 14, 2021, new elections to the Supervisory Board will be held as scheduled. In the course of the mediation process, agreement was reached between the Deutsche Balaton Group and the incumbent Supervisory Board of Biofrontera AG on the candidates for the Supervisory Board. The incumbent Supervisory Board therefore intends to propose the following candidates for election at the Annual General Meeting:
Biofrontera AG (BFRA) CEO Hermann Lübbert on Q3 2021 Results - Earnings Call Transcript
06:34pm, Thursday, 18'th Nov 2021 Seeking AlphaBiofrontera AG (BFRA) CEO Hermann Lübbert on Q3 2021 Results - Earnings Call Transcript
01:34pm, Thursday, 18'th Nov 2021
Biofrontera AG (BFRA) CEO Hermann Lübbert on Q3 2021 Results - Earnings Call Transcript
Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021
10:00pm, Wednesday, 17'th Nov 2021 GlobeNewswire Inc.
Leverkusen, Germany, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported it
Biofrontera earnings preview: what to expect
02:01pm, Tuesday, 16'th Nov 2021 Business Insider Markets
On November 17, Biofrontera will be reporting earnings from the last quarter. Wall Street analysts predict losses per share of 0.086. Go here to watch Biofrontera stock price in real-time ahead of
Biofrontera AG announces initiation of clinical studies
02:01pm, Tuesday, 16'th Nov 2021 GlobeNewswire Inc.
Leverkusen, Germany, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that tw
Biofrontera AG announces initiation of clinical studies
02:01pm, Tuesday, 16'th Nov 2021 Intrado Digital Media
Leverkusen, Germany, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the Company), an international biopharmaceutical company, announces that two clinical studies for its prescription drug Ameluz ® in the United States are being started with site initiations currently in progress, seven sites for the phase two study for the treatment of moderate- to- severe acne in adults as well as eight sites for the phase I safety study evaluating the safety of photodynamic therapy (PDT) with the simultaneous application of three tubes of Ameluz ® .
Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021
05:45am, Tuesday, 09'th Nov 2021
Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing i
Biofrontera reports preliminary approximate revenues for the month of September 2021
07:44am, Friday, 01'st Oct 2021
Leverkusen, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported prel
Biofrontera reports preliminary revenue for the month of August 2021
12:10pm, Wednesday, 08'th Sep 2021
Leverkusen, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported pre
Biofrontera AG's (BFRA) CEO Hermann Lübbert on Q2 2021 Results - Earnings Call Transcript
12:44pm, Friday, 20'th Aug 2021
Biofrontera AG's (BFRA) CEO Hermann Lübbert on Q2 2021 Results - Earnings Call Transcript
Biofrontera reports financial results for the six months ended June 30, 2021
11:47am, Thursday, 19'th Aug 2021
Leverkusen, Germany, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its